Novo Nordisk has upgraded is 2020 performance guidance on the back of less severe-than-expected de-stocking. Other than diabetic patients’ high vulnerability to COVID-19 warranting maintained stocking, the re-emerging threat of a second-wave of infections (especially in the US) could have been another contributing factor. However, given that diabetes pricing is expected to remain a tricky matter, we believe that any re-rating for Novo is dependent on its ability to reduce dependence on
09 Oct 2020
2020 guidance upgrade, ahead of the Q3 results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
2020 guidance upgrade, ahead of the Q3 results
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
09 Oct 2020 -
Author:
Surbhit Gupta -
Pages:
3
Novo Nordisk has upgraded is 2020 performance guidance on the back of less severe-than-expected de-stocking. Other than diabetic patients’ high vulnerability to COVID-19 warranting maintained stocking, the re-emerging threat of a second-wave of infections (especially in the US) could have been another contributing factor. However, given that diabetes pricing is expected to remain a tricky matter, we believe that any re-rating for Novo is dependent on its ability to reduce dependence on